Allurion Technologies Holdings Inc. has announced initial results from a case series evaluating the combination of the Allurion Program with low-dose tirzepatide therapy. The study involved 76 patients who received the Allurion Smart Capsule followed by low-dose tirzepatide, with doses ranging from 2.5mg to a maximum of 5.0mg, which is lower than standard tirzepatide dosing. After 12 months, participants experienced an average total body weight loss of 23% and a 14% increase in lean body mass as a percentage of total body weight. All patients remained adherent to tirzepatide throughout the study period. Additional data from this combination approach is being collected and is expected to be presented at upcoming medical meetings.